Julie Ann Tucker

Contact details

Type of addressPostal address
Postal codeYO10 5DD
CountryUnited Kingdom
Address lines
  • Biology
    University of York
    Wentworth Way
    York
    YO10 5DD

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations

Dr. Julie Ann Tucker

Research Associate

  1. 2021
  2. An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)

    Al-Khawaldeh, I., Alyassiri, M., Aldred, G., Basmadjian, C., Bordoni, C., Harnor, S. J., Heptinstall, A. B., Hobson, S., Jennings, C., Khalifa, S., Lebraud, H., Martin, M. P., Miller, D. C., Shrives, H., De Souza, J., Stewart, H., Temple, M. J., Thomas, H., Totobenazara, J., Tucker, J. A. & 12 others, Tudhope, S., Wang, L-Z., Bronowska, A., Cano, C., Endicott, J. A., Golding, B., Hardcastle, I. R., Hickson, I., Wedge, S., Willmore, E., Noble, M. E. M. & Waring, M. J., 2 Jul 2021, (E-pub ahead of print)

    Article in JOURNAL OF MEDICINAL CHEMISTRY

  3. Validation of IMS-MS as a screening tool to identify type II kinase inhibitors of FGFR1 kinase

    Beeston, H., Klein, T., Norman, R., Tucker, J. A., Anderson, M., Ashcroft, A. E. & Holdgate, G., 26 May 2021, (E-pub ahead of print)

    Article in Rapid Communications in Mass Spectrometry

  4. 2020
  5. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors

    Lochhead, P., Tucker, J. A., Tatum, N., Wang, J., Oxley, D., Kidger, A., Johnson, V., Cassidy, M., Gray, N., Noble, M. E. M. & Cook, S., 13 Mar 2020

    Article in Nature Communications

  6. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations

    Wilmes, S., Hafer, M., Vuorio, J., Tucker, J. A., Winkelmann, H., Lochte, S., Stanly, T. A., Pulgar Prieto, K. D., Poojari, C., Sharma, V., Richter, C. P., Kurre, R., Hubbard, S. R., Garcia, K. C., Moraga, I., Vattulainen, I., Hitchcock, I. S. & Piehler, J., 7 Feb 2020, (E-pub ahead of print)

    Article in Science

  7. 2019
  8. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4

    Tucker, J. A., Myers, S. M., Miller, D. C., Molyneux, L., Arasta, M., Bawn, R. H., Blackburn, T. J., Cook, S. J., Edwards, N., Endicott, J. A., Golding, B. T., Griffin, R. J., Hammonds, T., Hardcastle, I. R., Harnor, S. J., Heptinstall, A. B., Lochhead, P. A., Martin, M. P., Martin, N. C., Newell, D. R. & 10 others, Owen, P. J., Pang, L. C., Reuillon, T., Rigoreau, L. J. M., Thomas, H. D., Wang, L-Z., Wong, A-C., Noble, M. E. M., Wedge, S. R. & Cano, C., 15 Sep 2019

    Article in European Journal of Medicinal Chemistry

  9. 2018
  10. Cell-active Small Molecule Inhibitors of the DNA-damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

    Waszkowycz, B., Smith, K. M., McGonagle, A. E., Jordan, A. M., Acton, B., Fairweather, E. E., Griffiths, L. A., Hamilton, N. M., Hamilton, N. S., Hitchin, J. R., Hutton, C. P., James, D. I., Jones, C. D., Jones, S., Mould, D. P., Small, H. F., Stowell, A. I. J., Tucker, J. A., Waddell, I. D. & Ogilvie, D. J., 13 Dec 2018

    Article in JOURNAL OF MEDICINAL CHEMISTRY